Intra-Cellular Therapies Inc.

7 trials 4 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

3 Completed trials

11 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 4

Oversight events:

6 temporary halts across 2 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Bipolar disorder 2 Dementia Alzheimer's type 2 Dementia of the Alzheimer's type with delusions 1

Top IMPs

ITI-1284 4 LUMATEPERONE 3

All trials

7 total

A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Phase II 4 countries ITI-1284
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Phase II 5 countries ITI-1284
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Phase II 8 countries ITI-1284
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting

2023-503836-41-00 Phase III 4 countries LUMATEPERONE
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Phase II 6 countries ITI-1284
A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended

2024-513036-26-00 Phase III 2 countries LUMATEPERONE
A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended

2024-513037-20-00 Phase III 2 countries LUMATEPERONE

Showing 1–7 of 7 trials

← All sponsors A–Z